论文部分内容阅读
目的：探讨血清中细胞因子变化在恶性淋巴瘤（ＭＬ）中的意义。方法：采用放射免疫分析法及酶联免疫吸附法测定了４９例ＭＬ患者血清中白细胞介素２（ＩＬ－２）等５种细胞因子浓度。结果：除肿瘤坏死因子α（ＴＮＦα）外，大部分初治、复发患者中治疗前ＩＬ－２，可溶性白细胞介素２受体（ｓＩＬ－２Ｒ），ＩＬ－６，ＩＬ－８升高；治疗有反应的下降，完全缓解时与对照组无差异；治疗无反应的仍保持高水平。ＩＬ－２及ｓＩＬ－２Ｒ升高与患者的临床分期有关，Ⅲ、Ⅳ期患者较Ⅰ、Ⅱ期明显增高；ｓＩＬ－２Ｒ与肿瘤负荷有关；ＩＬ－６与患者有无Ｂ组症状相关，Ｂ组患者明显高于Ａ组，而与分期无关；ＩＬ－８升高与临床分期及Ｂ组症状有关，与其他临床血液学指标无关。结论：细胞因子的变化可以作为观察ＭＬ病情及监测治疗反应的一种手段。
Objective: To explore the significance of serum cytokine changes in malignant lymphoma (ML). METHODS: Serum concentrations of interleukin-2 (IL-2) and other cytokines in 49 patients with ML were determined by radioimmunoassay and enzyme-linked immunosorbent assay. Results: In addition to tumor necrosis factor-α (TNFα), pretreatment IL-2, soluble interleukin-2 receptor (IL-2R), IL-6, and IL-8 were increased in most newly diagnosed and relapsed patients. There was a decrease in response, and there was no difference in the complete remission with the control group; the treatment remained non-responsive and remained high. The elevated levels of IL-2 and sIL-2R were related to the clinical stage of the patients. The patients in stage III and IV were significantly higher than those in stage I and II. The level of sIL-2R was related to the tumor burden; IL-6 was related to the presence or absence of symptoms in group B, B The patients in the group were significantly higher than those in the A group, but not in the stage. The increase of IL-8 was related to the clinical stage and the symptoms in the group B. It was not related to other clinical hematology parameters. Conclusion: Changes in cytokines can be used as a means of observing the condition of ML and monitoring treatment response.